[BCG in reflux]

Urologe A. 1989 Jan;28(1):36-9.
[Article in German]

Abstract

Nine patients with radiologically proven vesicorenal reflux (3 bilateral, 4 unilateral, 2 with unilateral double-J stents) received intravesical bacillus Calmette-Guérin (BCG) as prophylactic treatment for recurrent superficial bladder carcinoma. One patient with a double-J stent suffered an attack of high fever, probably following obstruction of the stent. All other patients tolerated one cycle or two cycles (5 of 9 patients) of 6 weekly instillations without significant complications. There was no increased toxicity compared with a control group of 39 patients without reflux who were receiving BCG. Topical intravesical immunotherapy with BCG in patients with vesicorenal reflux can be given without a rise in the complication rate; indeed, in view of the multifocal appearance of urothelial carcinoma in this subgroup, this type of therapy even appears to be desirable.

Publication types

  • English Abstract

MeSH terms

  • Administration, Intravesical
  • Aged
  • Aged, 80 and over
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy*
  • Vesico-Ureteral Reflux / complications*
  • Vesico-Ureteral Reflux / etiology

Substances

  • BCG Vaccine